Clinical trial

Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

NCT00193180

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-05-01

PhasePHASE2

Study timeline

Study start (unknown)2005-05-01Date precision: month

Registry last updated2016-05-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

ImatinibDRUG · verified · RxNorm: imatinib

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

SCRI Development Innovations, LLClead sponsor

Novartiscollaborator

Aventis Pharmaceuticalscollaborator

Mapped research locations

NashvilleTennessee, United States1 CincinnatiOhio, United States1 OmahaNebraska, United States1 LouisvilleKentucky, United States1 Baton RougeLouisiana, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00193180 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.